NICE has today (10 January) published draft guidance for public consultation which does not recommend erenumab (Aimovig, Novartis) for preventing migraine. The draft guidance looks at erenumab for preventing chronic and episodic migraine (as defined by the International Headache Society) in adults who have 4 episodes or more of migraine every month where at least […]Continue Reading ...
Home News Professional Meta-Analysis: Botulinum A Tops Placebo for Chronic Migraine MONDAY, Jan. 7, 2019 — For chronic migraine, botulinum type A injections are superior to placebo after three months of therapy, according to a meta-analysis published in the January issue of Plastic and Reconstructive Surgery. Eva Bruloy, M.D., from the University Hospital of Picardie […]Continue Reading ...
lasmiditan Treatment for Migraine Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine INDIANAPOLIS, Nov. 14, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute treatment […]Continue Reading ...
CHOP Researcher: Findings may suggest more effective headache treatments Pediatric researchers have discovered common gene variants associated with migraines in African-American children. The research adds to knowledge of genetic influences on childhood migraine and may lead to future precision medicine treatments for African-American children with these intense headaches. “Scientists already know that migraines may run […]Continue Reading ...
FDA Approves Emgality (galcanezumab-gnlm) for the Preventive Treatment of Migraine in Adults INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults.1 Emgality offers a once-monthly, self-administered, subcutaneous […]Continue Reading ...
FDA Approves Ajovy (fremanezumab-vfrm) for Preventive Treatment of Migraine September 14, 2018 — Today, the US Food and Drug Administration (FDA) approved Ajovy (fremanezumab-vfrm) for the preventive treatment of migraine in adults. Ajovy is the second FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related […]Continue Reading ...
August 14, 2018 Research published today reveals a potential mechanism for migraine causation which could explain why women get more migraines than men. The study, in Frontiers in Molecular Biosciences, suggests that sex hormones affect cells around the trigeminal nerve and connected blood vessels in the head, with estrogens — at their highest levels in […]Continue Reading ...
June 30, 2018 If you’ve ever had a migraine, you know it’s different from a typical tension headache. A migraine is a type of headache that comes with its own set of symptoms like nausea, sensitivity to light, sound or smells, extreme fatigue or dizziness. According to the Migraine Research Foundation, approximately 12% of people […]Continue Reading ...
NEW HAVEN, Conn., Dec. 10, 2018 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced initial positive results from its ongoing long-term, open-label safety study of its oral calcitonin gene-related peptide (CGRP) receptor antagonist, rimegepant, for the acute treatment of migraine. Based upon this interim analysis (database cutoff of November 21, 2018) of […]Continue Reading ...
Oct 23 2018 Novartis announced today that the full data from the LIBERTY study of Aimovig® (erenumab) in episodic migraine patients who had tried and failed two to four prior preventive treatments have been published in the Lancet. Patients treated with Aimovig had significant improvements on all primary and secondary endpoints of the study. Aimovig […]Continue Reading ...
By slightly changing the body’s own molecules using a small inhaler, certain migraine patients can either cut down on medication or do without it completely. This is shown by a pilot study which has been published in the scientific journal Cephalalgia. Patients who suffer from migraine with aura, which is where they experience either sensory […]Continue Reading ...
Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved AJOVYTM (fremanezumab-vfrm) injection for the preventive treatment of migraine in adults. AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for […]Continue Reading ...
To decrease the substantial health and economic burden of migraine on individuals and society, researchers need to examine and address how the disease differs between women and men, according to a report from the Society for Women’s Health Research published in the August issue of the Journal of Women’s Health. Women shoulder a significant amount […]Continue Reading ...
INDIANAPOLIS, June 27, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today results from a post-hoc analysis which demonstrated efficacy of Emgality™ (galcanezumab-gnlm) in patients with episodic and chronic migraine who had previously failed preventive treatment with Botox®* (onabotulinumtoxinA). Detailed results from a post-hoc analysis of three Phase 3 studies (EVOLVE-1, EVOLVE-2 and […]Continue Reading ...
June 28, 2018 While it has been known that estrogen plays a role in migraine for women, new research shows that the female sex hormone may also play a role in migraine for men, according to a small study published in the June 27, 2018, online issue of Neurology®, the medical journal of the American […]Continue Reading ...
- New study shows link between secondhand smoke and cardiac arrhythmia
- DZIF scientists reveal problems with available diagnostics for Zika and chikungunya virus
- Breast cancers more likely to metastasize in young women within 10 years of giving birth
- Blood vessels can now be created perfectly in a petri dish
- Study identifies prominent socioeconomic and racial disparities in health behavior in Indiana
- Young-Onset Type 2 Diabetes Tied to Increased Hospitalization Risk
- For-profit nursing schools associated with lower performance on nurse licensure test
- Considering the culture of consent in medicine
- Researchers identify comprehensive guidelines for managing severe atopic dermatitis
- Analyzing proteins in blister fluid may classify burn severity more accurately
- Study finds higher suicide rates among youth who were Medicaid enrollees
- Opioid drugs often overprescribed to children for pain relief, say CHOP surgeons
- New biodegradable wound dressing material accelerates healing
- Life in Space May Take Toll on Spinal Muscles
- Bulldogs’ screw tails linked to human genetic disease
- Immunotherapy target identified for pediatric cancers
- Financial stress may increase heart disease risk in African Americans
- Scientists solve another piece of Ebola virus puzzle
- New project finds how endocrine disruptors interfere with thyroid functions
- Research finds decline in ketone body utilization when coronary circulation is reduced